Organization
University of Milano, European Institute of Oncology, Division of Early Drug Development
20 abstracts
4 posters
Abstract
Depicting oncologists' perceptions and knowledge of global disparities in conflicts of interest reporting: The ONCOTRUST-1 study.Org: Faculty of Medical Sciences, University Mohammed VI Polytechnic, National Institute of Oncology. Istenhegyi Géndiagnosztika Private Health Center Oncology Clinic, Evercare Hospital Dhaka, Kenyatta University Teaching,
Abstract
Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City (New Jersey, USA),
Abstract
Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).Org: Gustave Roussy Cancer Center, The Institute of Cancer Research/The Royal Marsden Hospital, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research, ISA Pharmaceuticals B.V., Regeneron Pharmaceuticals, Inc.,
Abstract
Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.Org: University Hospital Zurich, Aix-Marseille University CHU Timone, Hôpital de la Timone, Department of Cancer Medicine, Gustave Roussy Cancer Centre, Gustave Roussy Cancer Campus,
Abstract
Comprehensive analysis of TROP2, PD-L1, stromal (s)TILs, and HER2 expression patterns in patients (pts) with metastatic HR+HER2- breast cancer.Org: Dana-Farber Cancer Institute, University of Milan and European Institute of Oncology, IRCCS, Brigham and Women's Hospital, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology,
Abstract
INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC).Org: Genentech, Product Development Data Science, F. Hoffmann-La Roche Ltd., F. Hoffmann-La Roche Ltd, Roche Products Ltd., Product Development Oncology, F. Hoffmann-La Roche Ltd.,
Abstract
Unfavourable carcinoma of unknown primary (CUP) with gastrointestinal profile: A retrospective study.Org: Istituto Europeo di Oncologia IRCCS, Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, European Institute of Oncology IRCCS, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology (IEO),
Abstract
Cardiovascular events in patients receiving immuno-oncology agents, in phase I clinical trials: CAVIO study.Org: Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, European Institute of Oncology IRCCS, University of Milano, European Institute of Oncology, Division of Early Drug Development, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy,
Abstract
Impact of race and age on intrinsic subtype distribution and treatment decisions in metastatic breast cancer: Preliminary analysis of HARMONY (LCCC1829).Org: University of North Carolina at Chapel Hill, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, University of North Carolina School of Medicine, University of Milano, European Institute of Oncology, Division of Early Drug Development, Lineberger Comprehensive Cancer Center,
Abstract
Prognostic value of tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer (BC): A focus on inflammatory BC.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Northwestern University, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Washington University in St. Louis,
Abstract
Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).Org: Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck.Org: Moores Cancer Center, UC San Diego Health, University of California San Diego, La Jolla, CA, Institut Curie, Saint Cloud, France, Paris, France,
Abstract
Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).Org: Cliniques Universitaires Saint-Luc, Department of Drug Development and Innovation (D3i), Institut Curie, Saint Cloud, France, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development,
Abstract
Clinical characterization of responders to first line (chemo)immunotherapy in platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).Org: Head and Neck Cancer Medical Oncology 3 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Hemato-Oncology (DIPO), University of Milano, European Institute of Oncology, Division of Early Drug Development, Head and Neck Cancer Medical Department,
Abstract
ANALYSIS OF ABATACEPT TREATMENT RETENTION AND EFFICACY ACCORDING TO DISEASE DURATION AND TREATMENT LINE IN A REAL-WORLD SETTINGOrg: Bristol Myers Squibb, Deepscover, Biostatistics, Puteaux, France, ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands, Schulthess Klinik, Universitätsspital Basel, Rheumatology, Basel, Switzerland,
Abstract
ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS DETERMINES 2-YEAR RETENTION OF IV AND SC ABATACEPT IN PATIENTS WITH RA IN A REAL-WORLD SETTINGOrg: Bristol Myers Squibb, ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands, University of Leeds, University of Manchester and The Christie NHS Foundation Trust, Evangelical Hospital, Department of Internal Medicine, Vienna, Austria,
Abstract
ADALIMUMAB CLINICAL EFFICACY IS ASSOCIATED WITH RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY TITRE REDUCTION: A 6-MONTH PROSPECTIVE STUDYOrg: Rheumatology unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, L Sacco University Hospital, Pharmacoeconomy Centre, Chair of Pharmacology, University of Milano, European Institute of Oncology, Division of Early Drug Development,
Abstract
BAG3 PROTEIN: A PROMISING NOVEL BIOMARKER OF FIBROSIS IN SYSTEMIC SCLEROSISOrg: University of Salerno, FIBROSYS s.r.l., ASST Gaetano Pini-CTO, Dept of Rheumatology, Milan, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development, Research Center for Adult and Pediatric Rheumatic Diseases,
Abstract
BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDYOrg: UCB Pharma, ASST Gaetano Pini-CTO, Dept of Rheumatology, Milan, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development, Centre for Therapeutic Innovation, University of Bath,
Abstract
BETA2GPI AND TLR4 INTERACTION ON ENDOTHELIAL CELLS: A BRIDGE BETWEEN INNATE AND ADAPTIVE IMMUNITY IN APS Org: University of Milano, European Institute of Oncology, Division of Early Drug Development, Ist Auxologico Italiano, Milan, University of Parma, Parma, Italy,